Low-dose sodium nitrite attenuates myocardial ischemia and vascular ischemia-reperfusion injury in human models. 2013

Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
Wales Heart Research Institute, Cardiff University Medical School, Cardiff, United Kingdom.

OBJECTIVE The aim of this study was to assess the potential benefits of inorganic nitrite in 2 clinical models: stress-induced myocardial ischemia and whole-arm ischemia-reperfusion. BACKGROUND Inorganic nitrite, traditionally considered a relatively inert metabolite of nitric oxide, may exert vasomodulatory and vasoprotective effects. Despite promising results from animal models, few have shown effectiveness in human model systems, and none have fully translated to the clinical setting. METHODS In 10 patients with inducible myocardial ischemia, saline and low-dose sodium nitrite (NaNO₂) (1.5 μmol/min for 20 min) were administered in a double-blind fashion during dobutamine stress echocardiography, at separate visits and in a random order; long-axis myocardial function was quantified by peak systolic velocity (Vs) and strain rate (SR) responses. In 19 healthy subjects, flow-mediated dilation was assessed before and after whole-arm ischemia-reperfusion; nitrite was given before ischemia or during reperfusion. RESULTS Comparing saline and nitrite infusions, Vs and SR at peak dobutamine increased in regions exhibiting ischemia (Vs from 9.5 ± 0.5 cm/s to 12.4 ± 0.6 cm/s, SR from -2.0 ± 0.2 s(-1) to -2.8 ± 0.3 s(-1)), whereas they did not change in normally functioning regions (Vs from 12.6 ± 0.4 cm/s to 12.6 ± 0.6 cm/s, SR from -2.6 ± 0.3 s(-1) to -2.3 ± 0.1 s(-1)) (p < 0.001, analysis of variance). With NaNO2, the increment of Vs (normalized for increase in heart rate) increased only in poorly functioning myocardial regions (+122%, p < 0.001). Peak flow-mediated dilation decreased by 43% after ischemia-reperfusion when subjects received only saline (6.8 ± 0.7% vs. 3.9 ± 0.7%, p < 0.01); administration of NaNO2 before ischemia prevented this decrease in flow-mediated dilation (5.9 ± 0.7% vs. 5.2 ± 0.5%, p = NS), whereas administration during reperfusion did not. CONCLUSIONS Low-dose NaNO₂ improves functional responses in ischemic myocardium but has no effect on normal regions. Low-dose NaNO₂ protects against vascular ischemia-reperfusion injury only when it is given before the onset of ischemia.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012977 Sodium Nitrite Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines. Nitrite, Sodium

Related Publications

Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
June 2019, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
April 2016, Acta pharmacologica Sinica,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
October 1997, The Annals of thoracic surgery,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
January 2012, Advances in clinical and experimental medicine : official organ Wroclaw Medical University,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
September 2010, Expert opinion on therapeutic targets,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
December 2017, Oncotarget,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
April 2020, American journal of physiology. Lung cellular and molecular physiology,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
October 2000, Free radical biology & medicine,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
May 2009, Biochemical pharmacology,
Thomas E Ingram, and Alan G Fraser, and Robert A Bleasdale, and Elizabeth A Ellins, and Andrei D Margulescu, and Julian P Halcox, and Philip E James
November 2007, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!